JP2020180155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020180155A5 JP2020180155A5 JP2020120404A JP2020120404A JP2020180155A5 JP 2020180155 A5 JP2020180155 A5 JP 2020180155A5 JP 2020120404 A JP2020120404 A JP 2020120404A JP 2020120404 A JP2020120404 A JP 2020120404A JP 2020180155 A5 JP2020180155 A5 JP 2020180155A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- antibody
- impermeable
- conjugate according
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 37
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 16
- -1 phosphorothioate nucleic acids Chemical class 0.000 claims 14
- 230000003834 intracellular effect Effects 0.000 claims 13
- 101150001535 SRC gene Proteins 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 6
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 6
- 102000048616 Exportin-7 Human genes 0.000 claims 4
- 101000781458 Homo sapiens Exportin-7 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 208000012239 Developmental disease Diseases 0.000 claims 2
- 102000007999 Nuclear Proteins Human genes 0.000 claims 2
- 108010089610 Nuclear Proteins Proteins 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 210000000805 cytoplasm Anatomy 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000028774 intestinal disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022059465A JP2022091932A (ja) | 2013-08-29 | 2022-03-31 | 細胞透過性コンジュゲート及びその使用の方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361871729P | 2013-08-29 | 2013-08-29 | |
| US61/871,729 | 2013-08-29 | ||
| US201461939993P | 2014-02-14 | 2014-02-14 | |
| US61/939,993 | 2014-02-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537916A Division JP6736464B2 (ja) | 2013-08-29 | 2014-08-29 | 細胞透過性コンジュゲート及びその使用の方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022059465A Division JP2022091932A (ja) | 2013-08-29 | 2022-03-31 | 細胞透過性コンジュゲート及びその使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020180155A JP2020180155A (ja) | 2020-11-05 |
| JP2020180155A5 true JP2020180155A5 (enExample) | 2021-01-07 |
| JP7053730B2 JP7053730B2 (ja) | 2022-04-12 |
Family
ID=52587396
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537916A Active JP6736464B2 (ja) | 2013-08-29 | 2014-08-29 | 細胞透過性コンジュゲート及びその使用の方法 |
| JP2020120404A Active JP7053730B2 (ja) | 2013-08-29 | 2020-07-14 | 細胞透過性コンジュゲート及びその使用の方法 |
| JP2022059465A Pending JP2022091932A (ja) | 2013-08-29 | 2022-03-31 | 細胞透過性コンジュゲート及びその使用の方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537916A Active JP6736464B2 (ja) | 2013-08-29 | 2014-08-29 | 細胞透過性コンジュゲート及びその使用の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022059465A Pending JP2022091932A (ja) | 2013-08-29 | 2022-03-31 | 細胞透過性コンジュゲート及びその使用の方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10967070B2 (enExample) |
| EP (1) | EP3038639B1 (enExample) |
| JP (3) | JP6736464B2 (enExample) |
| KR (2) | KR102522346B1 (enExample) |
| CN (2) | CN105658230B (enExample) |
| AU (3) | AU2014312031A1 (enExample) |
| CA (1) | CA2922698C (enExample) |
| EA (1) | EA201690492A1 (enExample) |
| IL (1) | IL244296A0 (enExample) |
| MX (2) | MX386030B (enExample) |
| PH (1) | PH12016500395A1 (enExample) |
| SG (1) | SG11201601443PA (enExample) |
| WO (1) | WO2015031837A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170267784A1 (en) | 2014-10-23 | 2017-09-21 | Singh Molecular Medicine, Llc | Single domain antibodies directed against intracellular antigens |
| MX379450B (es) | 2014-10-23 | 2025-03-11 | Singh Biotechnology Llc | Anticuerpos de un solo dominio dirigidos contra antígenos intracelulares |
| CA2972986A1 (en) | 2015-01-16 | 2016-07-21 | City Of Hope | Cell penetrating antibodies |
| US20180243436A1 (en) * | 2015-08-06 | 2018-08-30 | City Of Hope | Therapeutic cell internalizing conjugates |
| US11661463B2 (en) | 2015-08-06 | 2023-05-30 | City Of Hope | Cell penetrating protein-antibody conjugates and methods of use |
| CN108473574A (zh) * | 2015-10-20 | 2018-08-31 | 索伦托治疗有限公司 | 细胞内递送化合物 |
| TWI746473B (zh) | 2015-11-02 | 2021-11-21 | 美商辛分子醫藥有限公司 | 針對細胞內抗原之單域抗體 |
| EP3386549A4 (en) * | 2015-12-10 | 2019-08-07 | City of Hope | Cell penetrating cyanine-coupled antibodies |
| KR20180059091A (ko) | 2016-11-25 | 2018-06-04 | 김정수 | 소비자 패션선호도 기반의 가상 피팅 방법, 그 시스템 및 시스템의 작동을 제어하기 위한 제어방법 |
| JP7227908B2 (ja) * | 2017-01-04 | 2023-02-22 | ソレント・セラピューティクス・インコーポレイテッド | 細胞表面チオールとの反応のためのチオール反応性基を含有する細胞内在化コンジュゲート |
| AU2018252193B2 (en) | 2017-04-14 | 2024-12-12 | Tallac Therapeutics, Inc. | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
| US11607457B2 (en) * | 2017-07-13 | 2023-03-21 | City Of Hope | Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same |
| WO2019014648A1 (en) * | 2017-07-13 | 2019-01-17 | City Of Hope | PEPTIDES CONJUGATED TO A PHOSPHOROTHIOATE AND METHODS OF USE |
| WO2019125033A1 (ko) * | 2017-12-22 | 2019-06-27 | (주)로피바이오 | 세포 내 침투능을 갖는 항 stat3 이중특이 항체 및 이를 포함하는 약학적 조성물 |
| KR20190076354A (ko) * | 2017-12-22 | 2019-07-02 | 주식회사 로피바이오 | 세포 내 침투능을 갖는 항 stat3 이중특이 항체를 포함하는, 염증성 질환 치료용 약학적 조성물 |
| JP7372237B2 (ja) | 2018-06-04 | 2023-10-31 | 中外製薬株式会社 | 細胞質内での半減期が変化した抗原結合分子 |
| US20220125891A1 (en) | 2018-06-06 | 2022-04-28 | Osaka University | Method for treating and/or preventing regnase-1-related disease |
| US20240110176A1 (en) * | 2020-05-22 | 2024-04-04 | City Of Hope | Phosphorothioate nucleic acid conjugates including dna editing enzymes |
| CN116615249A (zh) * | 2020-06-24 | 2023-08-18 | 萨普雷米科技有限公司 | 用于在药品中使用的皂苷衍生物 |
| WO2021261996A2 (en) * | 2020-06-24 | 2021-12-30 | Sapreme Technologies B.V. | Nhs-based saponin conjugates |
| WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
| WO2024129459A1 (en) | 2022-12-16 | 2024-06-20 | University Of Rochester | Repairmen! of barrier dysfunction in esophagus |
| WO2025106120A2 (en) * | 2023-06-01 | 2025-05-22 | The Regents Of The University Of California | Antibodies to stat3 decoy oligonucleotide |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| NZ255043A (en) | 1992-07-13 | 1997-03-24 | Eukarion Inc | Lipidized proteins and compositions thereof and their use in targeting proteins to intracellular compartments and enhancing organ uptake of them |
| EP0651805B1 (en) | 1992-07-17 | 2006-12-13 | Dana Farber Cancer Institute | Method of intracellular binding of target molecules |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| WO1995002422A1 (en) | 1993-07-12 | 1995-01-26 | Weltman Joel K | Method for conjugating nucleotides and nucleosides to disulfide-, maleimide-, and thiol-containing compounds |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| EP1007533B1 (en) * | 1996-08-27 | 2005-06-22 | University Of Utah Research Foundation | Bioconjugates and delivery of bioactive agents |
| ATE477273T1 (de) | 1998-12-01 | 2010-08-15 | Facet Biotech Corp | Humanisierte antikoerper gegen gamma-interferon |
| US6903077B1 (en) | 1999-01-04 | 2005-06-07 | University Of Vermont And State Agricultural College | Methods and products for delivering nucleic acids |
| DE60040755D1 (de) | 1999-12-01 | 2008-12-18 | Novartis Vaccines & Diagnostic | Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv) |
| US20040052762A1 (en) * | 2001-09-10 | 2004-03-18 | Hua Yu | Stat3 agonists and antagonists and therapeutic uses thereof |
| US20030158109A1 (en) | 2000-11-13 | 2003-08-21 | Klaus Giese | Metastatic breast and colon cancer regulated genes |
| KR20040058229A (ko) | 2001-10-22 | 2004-07-03 | 더 스크립스 리서치 인스티튜트 | 항체 표적화 화합물 |
| US20050042632A1 (en) | 2002-02-13 | 2005-02-24 | Sirna Therapeutics, Inc. | Antibodies having specificity for nucleic acids |
| US20040147027A1 (en) * | 2003-01-28 | 2004-07-29 | Troy Carol M. | Complex for facilitating delivery of dsRNA into a cell and uses thereof |
| AU2004316996A1 (en) | 2003-06-20 | 2005-09-15 | The Regents Of The University Of California | Polypeptide transduction and fusogenic peptides |
| US20070167388A1 (en) * | 2003-09-11 | 2007-07-19 | Universitätsklinikum Schleswig-Holstein Campus Lübeck | Nucleotide sequences promoting the trans-membrane transport of nucleic acids |
| AU2005217646A1 (en) | 2004-02-26 | 2005-09-09 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | A novel cofactor that modulates steroid receptor activities |
| WO2006017325A2 (en) | 2004-07-13 | 2006-02-16 | Cell Genesys, Inc. | Aav vector compositions and methods for enhanced expression of immunoglobulins the same |
| AU2006325030B2 (en) * | 2005-12-16 | 2012-07-26 | Cellectis | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
| US20070225213A1 (en) | 2006-03-23 | 2007-09-27 | Kosak Matthew K | Nucleic acid carriers for delivery of therapeutic agents |
| HRP20140172T1 (hr) * | 2006-05-30 | 2014-03-28 | Genentech, Inc. | Protutijela i imunokonjugati kao i njihove uporabe |
| WO2008008476A2 (en) * | 2006-07-12 | 2008-01-17 | The Regents Of The University Of California | Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups |
| CN101790385A (zh) * | 2007-07-12 | 2010-07-28 | 普罗森那技术公司 | 用于使化合物靶向多种选定器官、组织或肿瘤细胞的分子 |
| US20110129421A1 (en) | 2007-07-17 | 2011-06-02 | The General Hospital Corporation | Matrix metalloprotease targeting nucleic acids |
| MX2010001194A (es) * | 2007-07-31 | 2010-07-30 | Univ Louisiana State | Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones. |
| US20110218334A1 (en) | 2008-07-11 | 2011-09-08 | Alnylam Pharmaceuticals, Inc. | PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS |
| US20110212028A1 (en) * | 2008-09-16 | 2011-09-01 | Kariem Ahmed | Chemically modified cell-penetrating peptides for improved delivery of gene modulating compounds |
| US20100190691A1 (en) * | 2009-01-27 | 2010-07-29 | Trojan Technologies, Ltd | Delivery of nucleic acids using cell-penetrating peptides |
| HRP20230487T1 (hr) | 2009-02-13 | 2023-07-21 | Immunomedics, Inc. | Imunokonjugati s unutarstaničnom vezom koja se može rascijepiti |
| US8552167B2 (en) * | 2009-10-20 | 2013-10-08 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing |
| NZ586074A (en) * | 2010-06-10 | 2013-07-26 | Auckland Uniservices Ltd | LCLRP peptides, constructs and uses thereof |
| US20120122795A1 (en) | 2010-08-09 | 2012-05-17 | University Of Southern California | Accelerated extension of axons |
| US9045750B2 (en) | 2011-03-18 | 2015-06-02 | Yuelong Ma | Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3 |
| US9701740B2 (en) * | 2011-04-01 | 2017-07-11 | Yale University | Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair |
| EP2751270B1 (en) | 2011-08-29 | 2018-08-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
-
2014
- 2014-08-29 CA CA2922698A patent/CA2922698C/en active Active
- 2014-08-29 AU AU2014312031A patent/AU2014312031A1/en not_active Abandoned
- 2014-08-29 WO PCT/US2014/053549 patent/WO2015031837A1/en not_active Ceased
- 2014-08-29 CN CN201480055531.9A patent/CN105658230B/zh active Active
- 2014-08-29 SG SG11201601443PA patent/SG11201601443PA/en unknown
- 2014-08-29 CN CN202010254165.7A patent/CN111437395A/zh active Pending
- 2014-08-29 MX MX2016002643A patent/MX386030B/es unknown
- 2014-08-29 KR KR1020167008310A patent/KR102522346B1/ko active Active
- 2014-08-29 EP EP14839093.3A patent/EP3038639B1/en active Active
- 2014-08-29 JP JP2016537916A patent/JP6736464B2/ja active Active
- 2014-08-29 EA EA201690492A patent/EA201690492A1/ru unknown
- 2014-08-29 KR KR1020217031968A patent/KR20210123433A/ko not_active Ceased
-
2016
- 2016-02-25 IL IL244296A patent/IL244296A0/en unknown
- 2016-02-29 US US15/056,777 patent/US10967070B2/en active Active
- 2016-02-29 PH PH12016500395A patent/PH12016500395A1/en unknown
- 2016-02-29 MX MX2021009190A patent/MX2021009190A/es unknown
-
2020
- 2020-03-09 AU AU2020201725A patent/AU2020201725B2/en active Active
- 2020-07-14 JP JP2020120404A patent/JP7053730B2/ja active Active
-
2021
- 2021-02-24 US US17/184,237 patent/US20210330804A1/en active Pending
-
2022
- 2022-03-31 JP JP2022059465A patent/JP2022091932A/ja active Pending
- 2022-07-27 AU AU2022209292A patent/AU2022209292A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020180155A5 (enExample) | ||
| JP6965311B2 (ja) | 二重特異的融合タンパク質 | |
| Deshaies | Multispecific drugs herald a new era of biopharmaceutical innovation | |
| Sedykh et al. | Bispecific antibodies: design, therapy, perspectives | |
| Smith | New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics | |
| JP7173618B2 (ja) | アルファ－シヌクレインに対する抗体およびその用途 | |
| JP2020529863A (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| EP2915818A2 (en) | Dual variable domain immunoglobulins and uses thereof | |
| JP6156144B2 (ja) | 親和性複合体に対する抗体 | |
| JP2018505870A5 (enExample) | ||
| US20130195871A1 (en) | Dual variable domain immunoglobulins and uses thereof | |
| US20140271457A1 (en) | Dual Specific Binding Proteins Directed Against TNF | |
| SG192489A1 (en) | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof | |
| RU2662933C2 (ru) | Антитела против cd26 и их применение | |
| MX2010013239A (es) | Inmunoglobulinas de dominio variable doble y usos de las mismas. | |
| JP2024178212A (ja) | Ｃｄ７３免疫チェックポイントを抑制するためのモノクローナル抗体及びその抗原結合断片並びにその使用 | |
| KR20130048242A (ko) | 항-종양 항원 항체 및 이용 방법 | |
| JP7703027B2 (ja) | 抗ｌａｇ－３のモノクローナル抗体、その抗原結合性断片及びその使用 | |
| CN112955548B (zh) | 叶酸受体α特异性抗体 | |
| JP2013527129A (ja) | トランスフェリン受容体に対する抗体及び鉄依存性腫瘍の免疫療法のためのその使用 | |
| MX2010013236A (es) | Inmunoglobulinas de dominio variable doble y usos de las mismas. | |
| TW201333035A (zh) | 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白 | |
| JPWO2019175223A5 (enExample) | ||
| Chen et al. | A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy | |
| US20120009196A1 (en) | Monoclonal antibodies against hepatitis c virus core protein |